Hypoxia-inducible factor and mammalian target of rapamycin pathway markers in urothelial carcinoma of the bladder: Possible therapeutic implications

BJU International

Volumn 107, Issue 5, 2011, Pages 844-849

  Tickoo, Satish K ^a   Milowsky, Matthew I ^a,b   Dhar, Nitin ^a   Dudas, Maria E ^a   Gallagher, David J ^a   Al Ahmadie, Hikmat ^a   Gopalan, Anuradha ^a   Fine, Samson W ^a   Ishill, Nicole ^a   Bajorin, Dean F ^a,b   Reuter, Victor E ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

bladder carcinoma; hypoxia inducible factor; immunohistochemistry; mammalian target of rapamycin

Indexed keywords

HYPOXIA INDUCIBLE FACTOR 1ALPHA; INITIATION FACTOR 4E BINDING PROTEIN 1; MAMMALIAN TARGET OF RAPAMYCIN; PROTEIN S6; VASCULOTROPIN RECEPTOR 2;

ARTICLE; BLADDER CARCINOMA; CANCER INVASION; CANCER STAGING; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; PRIORITY JOURNAL; PROTEIN EXPRESSION; TRANSITIONAL CELL CARCINOMA; TUMOR CELL; TUMOR VASCULARIZATION;

ANTINEOPLASTIC AGENTS; CARCINOMA, TRANSITIONAL CELL; CELL HYPOXIA; CELL LINE, TUMOR; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; IMMUNOHISTOCHEMISTRY; SIGNAL TRANSDUCTION; SIROLIMUS; TOR SERINE-THREONINE KINASES; URINARY BLADDER NEOPLASMS;

EID: 78649676757     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2010.09517.x     Document Type: Article

References (32)

1. Dovedi SJ, Davies BR,. Emerging targeted therapies for bladder cancer: a disease waiting for a drug. Cancer Metastasis Rev 2009; 28: 355-67
2. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2009. CA Cancer J Clin 2009; 59: 225-49
3. von der Maase H, Hansen SW, Roberts JT, et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol 2000; 18: 3068-77
4. McCaffrey JA, Hilton S, Mazumdar M, et al. Phase II trial of docetaxel in patients with advanced or metastatic transitional-cell carcinoma. J Clin Oncol 1997; 15: 1853-7 (Pubitemid 27209514)
5. Youssef RF, Mitra AP, Bartsch G Jr, et al. Molecular targets and targeted therapies in bladder cancer management. World J Urol 2009; 27: 9-20
6. Gallagher DJ, Milowsky MI, Bajorin DF,. Advanced bladder cancer: status of first-line chemotherapy and the search for active agents in the second-line setting. Cancer 2008; 113: 1284-93
7. Philips S, Sanford B, Halabi S, et al. Phase II study of cisplatin, gemcitabine and gefitinib for advanced urothelial carcinoma: Analysis of the second cohort of CALGB 90102. J Clin Oncol (Meeting Abstracts) 2006 24 (18S): 4578
8. Hussain MH, MacVicar GR, Petrylak DP, et al. Trastuzumab, paclitaxel, carboplatin, and gemcitabine in advanced human epidermal growth factor receptor-2/neu-positive urothelial carcinoma: results of a multicenter phase II National Cancer Institute trial. J Clin Oncol 2007; 25: 2218-24 (Pubitemid 46954646)
9. Bradley DA, Dunn R, Nanus D, et al. Randomized, double-blind, placebocontrolled phase II trial of maintenance sunitinib versus placebo after chemotherapy for patients with advanced urothelial carcinoma: scientific rationale and study design. Clin Genitourin Cancer 2007; 5: 460-3 (Pubitemid 351219702)
10. Gallagher DJ, Milowsky MI, Gerst SR, et al. Final results of a phase II study of sunitinib in patients with relapsed or refractory urothelial carcinoma. J Clin Oncol (Meeting Abstracts) 2008 26 (15S): 5082
11. Sonpavde G, Jian W, Liu H, Wu MF, Shen SS, Lerner SP,. Sunitinib malate is active against human urothelial carcinoma and enhances the activity of cisplatin in a preclinical model. Urol Oncol 2009; 27: 391-9
12. Chiong E, Lee I-L, Dadbin A, et al. Effects of mTOR inhibitor everolimus (RAD001) on bladder cancer cells. J Urol 2009; 181: (4 Suppl.): 406 (abstract)
13. Patel AR, Larchian WA, Smith AK, et al. Quantification of Sunitinib's antitumor effects in a localized orthotopic bladder cancer model. J Urol 2009; 181: (4 Suppl): 409 (abstract)
14. Mansure JJ, Nassim R, Chevalier S, Rocha J, Scarlata E, Kassouf W,. Inhibition of mammalian target of rapamycin as a therapeutic strategy in the management of bladder cancer. Cancer Biol Ther 2009; 8: 2339-47
15. Wenger RH, Stiehl DP, Camenisch G,. Integration of oxygen signaling at the consensus HRE. Sci STKE 2005; 306: re12
16. Garcia JA, Danielpour D,. Mammalian target of rapamycin inhibition as a therapeutic strategy in the management of urologic malignancies. Mol Cancer Ther 2008; 7: 1347-54
17. Bochner BH, Cote RJ, Weidner N, et al. Angiogenesis in bladder cancer: relationship between microvessel density and tumor prognosis. J Natl Cancer Inst 1995; 87: 1603-12
18. Nguyen M, Watanabe H, Budson AE, et al. Elevated levels of the angiogenic peptide basic fibroblast growth factor in urine of bladder cancer patients. J Natl Cancer Inst 1993; 85: 241-2 (Pubitemid 23046901)
19. Motzer RJ, Molina AM,. Targeting renal cell carcinoma. J Clin Oncol 2009; 27: 3274-6
20. Mabuchi S, Altomare DA, Cheung M, et al. RAD001 inhibits human ovarian cancer cell proliferation, enhances cisplatin-induced apoptosis, and prolongs survival in an ovarian cancer model. Clin Cancer Res 2007; 13: 4261-70 (Pubitemid 47105991)
21. Fechner G, Classen K, Schmidt D, et al. Rapamycin inhibits in vitro growth and release of angiogenetic factors in human bladder cancer. Urology 2009; 73: 665-8
22. Cloughesy TF, Yoshimoto K, Nghiemphu P, et al. Antitumor activity of rapamycin in a Phase I trial for patients with recurrent PTEN-deficient glioblastoma. Plos Med 2008; 5: e8
23. Wu X, Obata T, Khan Q, Highshaw RA, et al. The phosphatidylinositol-3 kinase pathway regulates bladder cancer cell invasion. BJU Int 2004; 93: 143-50 (Pubitemid 38112985)
24. Chai CY, Chen WT, Hung WC, et al. Hypoxia-inducible factor-1alpha expression correlates with focal macrophage infiltration, angiogenesis and unfavourable prognosis in urothelial carcinoma. J Clin Pathol 2008; 61: 658-64
25. Ioachim E, Michael M, Salmas M, et al. Hypoxia-inducible factors HIF-1alpha and HIF-2alpha expression in bladder cancer and their associations with other angiogenesis-related proteins. Urol Int 2006; 77: 255-63 (Pubitemid 44567817)
26. Nadaoka J, Horikawa Y, Saito M, et al. Prognostic significance of HIF-1 alpha polymorphisms in transitional cell carcinoma of the bladder. Int J Cancer 2008; 122: 1297-302 (Pubitemid 351287229)
27. Tickoo SK, Alden D, Olgac S, et al. Immunohistochemical expression of hypoxia inducible factor-1alpha and its downstream molecules in sarcomatoid renal cell carcinoma. J Urol 2007; 177: 1258-63 (Pubitemid 46436019)
28. Ma L, Teruya-Feldstein J, Bonner P, et al. Identification of S664 TSC2 phosphorylation as a marker for extracellular signal-regulated kinase-mediated mTOR activation in tuberous sclerosis and human cancer. Cancer Res 2007; 67: 7106-12 (Pubitemid 47206537)
29. Bellmunt J, Maroto P, Mellado B, et al. Phase II study of sunitinib as first line treatment in patients with advanced urothelial cancer ineligible for cisplatin-based chemotherapy. ASCO, Genitourinary Cancers Symposium, 2008 (abstract)
30. Hahn NM, Stadler WM, Zon RT, et al. A multicentric phase II study of cisplatin, gemcitabine and bevacizumab as first-line chemotherapy for metastatic urothelial carcinoma: Hoosier Oncology Group GU-0475. J Clin Oncol 2009; 27: 15 s (suppl; abstr 5018)
31. Jones RJ, Tamsin B, Fennell M, et al. The impact of delay in cryo-fixation on biomarkers of Src tyrosine kinase activity in human breast and bladder cancers. Cancer Chemother Pharmacol 2008; 61: 23-32 (Pubitemid 47512622)
32. Pinter F, Papay J, Almasi A, et al. Epidermal growth factor receptor (EGFR) high gene copy number and activating mutations in lung adenocarcinomas are not consistently accompanied by positivity for EGFR protein by standard immunohistochemistry. J Mol Diagn 2008; 10: 160-8 (Pubitemid 351428398)